Overall burden and impact on health-related quality of life associated with intravesical treatment of patients with non-muscle invasive bladder cancer in the United States
Participants recently treated with intravesical therapies expressed intent to complete the full treatment course and willingness to try new therapies if needed. Participants reported high NMIBC symptom burden and work impairment negatively impacting their well-being, despite receiving intravesical treatment.
Authors
- Todor I. Totev (ORCID: https://orcid.org/0000-0003-0253-325X)
- Anabelle Tardif‐Samson (ORCID: https://orcid.org/0009-0009-5118-1909)
- Andrea Ireland
- Dominic Pilon (ORCID: https://orcid.org/0000-0002-6093-7167)
- Aditi Shah (ORCID: https://orcid.org/0009-0001-3971-0742)
- Patrick Lefèbvre (ORCID: https://orcid.org/0000-0002-2216-5442)
Institutions
- Johnson & Johnson (United States) (US)
- Janssen (United States) (US)
- Janssen Scientific Affairs (United States)
- Analysis Group (United States) (US)
Publication Details
- Journal
- Current Medical Research and Opinion
- Published
- 2024-10-03
- DOI
- https://doi.org/10.1080/03007995.2024.2411424
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00